UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 16.

Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, J; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, M; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; Moos, R von; Zaman, K; Goldhirsch, A; Swiss Group for Clinical Cancer Research (SAKK) (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Annals of Oncology, 28(2):305-312.

Pestalozzi, B; Fink, D (2016). Aszites. In: Kreuzer, Karl-Anton; Beyer, Jörg. Hämatologie und Onkologie : fallorientierte Darstellung - rationale Diagnostik und Therapie. Stuttgart: George Thieme Verlag, 88-89.

Dedes, K; Pestalozzi, B; Fink, D (2016). Neoplasien der weiblichen Geschlechtsorgane: Ovarial- und Tubenkarzinom. In: Kreuzer, K A; Beyer, J. Hämatologie und Onkologie. Fallorientierte Darstellung – rationale Diagnostik und Therapie. Stuttgart: Thieme, 385-390.

Suter, C; Franzen, D; Pestalozzi, B (2013). Fieber in Neutropenie. Praxis, 102(22):1341-1350.

Hofer, S; Mengele, K; Stemmler, H J; Schmitt, M; Pestalozzi, B (2012). Intrathecal trastuzumab: dose matters. Acta Oncologica, 51(7):955-956.

Joerger, M; Matter-Walstra, K; Früh, M; Kühnel, U; Szucs, T; Pestalozzi, B; Schwenkglenks, M (2011). Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of Oncology, 22(3):567-574.

Heinrich, S; Pestalozzi, B; Lesurtel, M; Berrevoet, F; Laurent, S; Delpero, J R; Raoul, J L; Bachellier, P; Dufour, P; Moehler, M; Weber, A; Lang, H; Rogiers, X; Clavien, P A (2011). Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer, 11:346.

Achtari, C; Fink, D; Günthert, A R; Huober, J; Pestalozzi, B; Petignat, P; von Moos, R; Sessa, C (2011). Bevacizumab in the primary treatment of epithelial ovarian cancer – some comments on the latest results. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 35(1):35-38.

Matter-Walstra, K; Schwenkglenks, M; Szucs, T D; Pestalozzi, B (2011). How to get involved in a health economic analysis: an introduction for clinical researchers. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 31(2):144-146.

Weisshaupt, C; Budak, K; Pestalozzi, B (2011). Nebenwirkungen neuerer onkologischer Therapien. Praxis, 100(15):885-891.

Rochlitz, C; Senn, H-J; Betticher, D; Helbling, D; von Moos, R; Pestalozzi, B; Thürlimann, B; Uebelhart, D; Aapro, M (2010). Der Einsatz von Bisphosphonaten bei der Behandlung solider Tumoren. Swiss Medical Forum, 10(34):562-564.

Lübbe, J; Anliker, M; Bernier, J; Borner, M; Dummer, R; Helbling, D; Hohl, D; Hunziker, T; Itin, P; Köberle, D; Pestalozzi, B; Rauch, D; Surber, C (2009). Kutane Nebenwirkungen der Therapie mit EGFR-Inhibitoren Klinische Einteilung und Behandlung. Dermatologica Helvetica, (5):19-23.

Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, Christian; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the swiss group for clinical cancer research SAKK. Annals of Oncology, 19(7):1288 -1292 .

Theurillat, J P; Zürrer-Härdi, U; Varga, Z; Barghorn, A; Saller, E; Frei, C; Storz, M; Behnke, S; Seifert, Burkhardt; Fehr, M; Fink, D; Rageth, C; Linsenmeier, C; Pestalozzi, B; Chen, Y T; Knuth, A; Jäger, D; Moch, H (2008). Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. International Journal of Cancer, 122(7):1585-1591.

Theurillat, J P; Zürrer-Härdi, U; Varga, Z; Storz, M; Probst-Hensch, N M; Seifert, Burkhardt; Fehr, M K; Fink, D; Ferrone, S; Pestalozzi, B; Jungbluth, A A; Chen, Y T; Jäger, D; Knuth, A; Moch, H (2007). NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunology, Immunotherapy, 56(11):1723-1731.

Pestalozzi, B; Schwendener, R; Sauter, C (1992). Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Annals of Oncology, 3(6):445-449.

This list was generated on Sat Jul 22 06:19:31 2017 CEST.